Cargando…

CAR T-cell therapy for follicular lymphoma and mantle cell lymphoma

Patients with relapsed and/or refractory (R/R) follicular lymphoma (FL) and mantle cell lymphoma (MCL) have a poor prognosis with anticipated short progression-free and overall survivals. Two CD19-directed chimeric antigen receptor T-cell (CAR T) therapies are approved in the United States for R/R F...

Descripción completa

Detalles Bibliográficos
Autores principales: Mohty, Razan, Kharfan-Dabaja, Mohamed A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9761215/
https://www.ncbi.nlm.nih.gov/pubmed/36544864
http://dx.doi.org/10.1177/20406207221142133
_version_ 1784852660631896064
author Mohty, Razan
Kharfan-Dabaja, Mohamed A.
author_facet Mohty, Razan
Kharfan-Dabaja, Mohamed A.
author_sort Mohty, Razan
collection PubMed
description Patients with relapsed and/or refractory (R/R) follicular lymphoma (FL) and mantle cell lymphoma (MCL) have a poor prognosis with anticipated short progression-free and overall survivals. Two CD19-directed chimeric antigen receptor T-cell (CAR T) therapies are approved in the United States for R/R FL, namely, axicabtagene ciloleucel (axi-cel) and tisagenlecleucel. The results of ZUMA-5 and ELARA studies led to the approval of axi-cel and tisagenlecleucel, respectively, after demonstrating high overall (ORR) and complete response (CR) rates in this high-risk population of FL patients who had received a median of 3 (range = 2–4) and 4 (range = 2–13) prior lines of therapies, respectively. For instance, the ORR for ZUMA-5 was 94% (CR = 79%), and for ELARA, it was 86% (CR = 69.1%). Pertaining to MCL, brexucabtagene autoleucel is approved for R/R MCL based on results of the ZUMA-2 study. In the latter study, despite the fact that all R/R MCL patients had been exposed to prior Bruton’s tyrosine kinase inhibitors, the reported ORR was 91%, with 68% achieving a CR. These results undoubtedly demonstrate a strong efficacy of CAR T therapy in both R/R FL and MCL; yet, one must acknowledge the relatively short follow-up time of all aforementioned studies. Thus, longer follow-up showing durability of responses and long-term safety is definitely needed.
format Online
Article
Text
id pubmed-9761215
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-97612152022-12-20 CAR T-cell therapy for follicular lymphoma and mantle cell lymphoma Mohty, Razan Kharfan-Dabaja, Mohamed A. Ther Adv Hematol Recent Advances in Immunotherapy for Lymphoma and Multiple Myeloma Patients with relapsed and/or refractory (R/R) follicular lymphoma (FL) and mantle cell lymphoma (MCL) have a poor prognosis with anticipated short progression-free and overall survivals. Two CD19-directed chimeric antigen receptor T-cell (CAR T) therapies are approved in the United States for R/R FL, namely, axicabtagene ciloleucel (axi-cel) and tisagenlecleucel. The results of ZUMA-5 and ELARA studies led to the approval of axi-cel and tisagenlecleucel, respectively, after demonstrating high overall (ORR) and complete response (CR) rates in this high-risk population of FL patients who had received a median of 3 (range = 2–4) and 4 (range = 2–13) prior lines of therapies, respectively. For instance, the ORR for ZUMA-5 was 94% (CR = 79%), and for ELARA, it was 86% (CR = 69.1%). Pertaining to MCL, brexucabtagene autoleucel is approved for R/R MCL based on results of the ZUMA-2 study. In the latter study, despite the fact that all R/R MCL patients had been exposed to prior Bruton’s tyrosine kinase inhibitors, the reported ORR was 91%, with 68% achieving a CR. These results undoubtedly demonstrate a strong efficacy of CAR T therapy in both R/R FL and MCL; yet, one must acknowledge the relatively short follow-up time of all aforementioned studies. Thus, longer follow-up showing durability of responses and long-term safety is definitely needed. SAGE Publications 2022-12-16 /pmc/articles/PMC9761215/ /pubmed/36544864 http://dx.doi.org/10.1177/20406207221142133 Text en © The Author(s), 2022 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Recent Advances in Immunotherapy for Lymphoma and Multiple Myeloma
Mohty, Razan
Kharfan-Dabaja, Mohamed A.
CAR T-cell therapy for follicular lymphoma and mantle cell lymphoma
title CAR T-cell therapy for follicular lymphoma and mantle cell lymphoma
title_full CAR T-cell therapy for follicular lymphoma and mantle cell lymphoma
title_fullStr CAR T-cell therapy for follicular lymphoma and mantle cell lymphoma
title_full_unstemmed CAR T-cell therapy for follicular lymphoma and mantle cell lymphoma
title_short CAR T-cell therapy for follicular lymphoma and mantle cell lymphoma
title_sort car t-cell therapy for follicular lymphoma and mantle cell lymphoma
topic Recent Advances in Immunotherapy for Lymphoma and Multiple Myeloma
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9761215/
https://www.ncbi.nlm.nih.gov/pubmed/36544864
http://dx.doi.org/10.1177/20406207221142133
work_keys_str_mv AT mohtyrazan cartcelltherapyforfollicularlymphomaandmantlecelllymphoma
AT kharfandabajamohameda cartcelltherapyforfollicularlymphomaandmantlecelllymphoma